An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials. The DSMB Recommended the Phase 3 Trials of Simufilam Continue as Planned, Without Modification AUSTIN, Texas , Sept.
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease. Results corroborate prior research from other academic researchers. These data once again confirm the biological activity of simufilam. AUSTIN, Texas , Sept.
AUSTIN, Texas , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the following investor conferences.
Results of a randomized, controlled trial of oral simufilam in Alzheimer’s disease announced July 2023 . Over 1,587 patients now enrolled in Phase 3 studies of simufilam in Alzheimer’s disease, an increase of over 340 patients in the last three months.
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease. Drug Effects Favored Mild Alzheimer’s Disease. In Mild Alzheimer’s, Simufilam Improved Cognition Scores Over 6 Months. In Mild Alzheimer’s, Simufilam Stabilized Cognition
Overactive mTOR Plays a Key Role in Aging and Alzheimer’s Disease. Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect. Research is Published in Frontiers in Aging , a Peer-reviewed Journal . AUSTIN, Texas , June 27, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research , a Peer-Reviewed Journal . AUSTIN, Texas , June 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
AUSTIN, Texas , June 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City .
The Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease. Primary Outcome Measures Are Safety and Change in Cognition Scores. Top-line Clinical Results of the CMS Are Expected in Q3 2023.
New in vitro data from Europe show that simufilam can reverse altered filamin A protein (FLNA) in pituitary tumor cells, leading to improved cell signaling. Data suggest FLNA is a central factor influencing pituitary tumor cell behavior. Data to be presented at the European Society of Endocrinology